A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

We report interim safety and immunogenicity findings from an ongoing phase 1/2 study of BNT162b2 in healthy Japanese adults. Participants were randomized 3:1 to receive 2 intramuscular injections of 30 μg BNT162b2 or placebo 21 days apart. Overall, 160 individuals were randomized: 119 received BNT16...

Descripción completa

Detalles Bibliográficos
Autores principales: Haranaka, Miwa, Baber, James, Ogama, Yoichiro, Yamaji, Masako, Aizawa, Masakazu, Kogawara, Osamu, Scully, Ingrid, Lagkadinou, Eleni, Türeci, Ӧzlem, Şahin, Uğur, Dormitzer, Philip R., Gruber, William C., Lockhart, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671474/
https://www.ncbi.nlm.nih.gov/pubmed/34907170
http://dx.doi.org/10.1038/s41467-021-27316-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671474/
https://www.ncbi.nlm.nih.gov/pubmed/34907170
http://dx.doi.org/10.1038/s41467-021-27316-2

Ejemplares similares